Seneca Biopharma, a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, has completed its new cell manufacturing facility in Suzhou, China.
Seneca Biopharma, Inc., (NASDAQ: SNCA), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, announced today that Seneca's Executive Chairman, Ken Carter, will present at both Sachs Associates 3rd Annu